Business
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment Proprietary MISBA Duo technology is the first platform to enable simultaneous, controlled upregulation and downregulation of two targets R&D programme with Ono Venture Investment builds on insights from first generation platform, and targets an undisclosed rare triplet repeat disorder Cambridge, UK, 06 October 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlockin
About this update from Ono Pharmaceutical Co., Ltd.
[{"type":"image","alt":"Harness Therapeutics","displaySize":"","headline":null,"caption":"Harness Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/b83a61b2bd93fe7c0bfe5d7a4cdf0dc1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HVeXB_CDIZ_pgqO.DJi5Qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b83a61b2bd93fe7c0bfe5d7a4cdf0dc1","width":300,"height":63}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":492,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/f54da337742b1fe6933d17ba652c381f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LcT0Ct32k0a2CrsTyeBbag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f54da337742b1fe6933d17ba652c381f","width":492,"height":102}}},{"type":"text","content":"Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment","length":115,"tagName":"p"},{"type":"text","content":"Proprietary MISBA Duo technology is the first platform to enable simultaneous, controlled upregulation and downregulation of two targets","length":136,"tagName":"p"},{"type":"text","content":"R&D programme with Ono Venture Investment builds on insights from first generation platform, and targets an undisclosed rare triplet repeat disorder","length":152,"tagName":"p"},{"type":"text","content":"Cambridge, UK, 06 October 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the establishment of the second generation of its MISBA® (microRNA site blocking ASO) platform, MISBA Duo. The first application of this platform is a new R&D programme, supported by Ono Venture Investment, Inc. (‘OVI’), the corporate venture capital arm of Ono Pharmaceutical Co., Ltd.","length":495,"tagName":"p"},{"type":"text","content":"Harness’ MISBA platform is designed to enable controlled, target-specific upregulation. MISBA Duo builds on this foundation to deliver, for the first time, bimodal modulation: simultaneous upregulation of one target and downregulation of a...